Information Provided By:
Fly News Breaks for March 7, 2017
TGTX
Mar 7, 2017 | 06:37 EDT
Ladenburg Thalmann analyst Matt Kaplan raised his price target for TG Therapeutics to $30 from $28 after the Phase 3 study of TG-1101 met its primary endpoint "with a highly statistically significant result." The analyst reiterates a Buy rating on the shares.
News For TGTX From the Last 2 Days
TGTX
Apr 19, 2024 | 10:46 EDT
Bullish option flow detected in TG Therapeutics with 1,058 calls trading, 1.2x expected, and implied vol increasing over 2 points to 100.79%. Jun-24 12 puts and Jun-24 17 calls are the most active options, with total volume in those strikes near 600 contracts. The Put/Call Ratio is 0.46. Earnings are expected on April 29th.
TGTX
TGTX
TGTX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.